Acumen Pharmaceuticals, Inc. Common Stock
Veridion Score
Composite trend over time
Why is ABOS moving today?
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ABOS.
ABOS insider activity
Acumen Pharmaceuticals, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $19.4M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-17 | 2026-06-17 | Porter Derrell | Insider | sell | $2.33 | 13,040 | 35,500 | $30K | SEC Form 4 |
| 2026-06-17 | 2026-06-17 | Porter Derrell | Insider | buy | $1.07 | 13,040 | 48,540 | $14K | SEC Form 4 |
| 2026-06-17 | 2026-06-16 | Porter Derrell | Insider | sell | $2.33 | 12,800 | 35,500 | $30K | SEC Form 4 |
| 2026-06-17 | 2026-06-15 | Porter Derrell | Insider | sell | $2.35 | 6,460 | 48,300 | $15K | SEC Form 4 |
| 2026-06-17 | 2026-06-15 | Porter Derrell | Insider | buy | $1.07 | 6,460 | 54,760 | $7K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 50 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moABOS contract awards, year to date.
Public federal awards linked to this ticker.
ABOS lobbying filings, year to date.
Registered lobbying filings matched to Acumen Pharmaceuticals, Inc. Common Stock.